Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Pain and Headache Reports
Published in: Current Pain and Headache Reports 8/2016

01-08-2016 | Migraine and Beyond (R Cowan, Section Editor)

Diverse Physiological Roles of Calcitonin Gene-Related Peptide in Migraine Pathology: Modulation of Neuronal-Glial-Immune Cells to Promote Peripheral and Central Sensitization

Author: Paul L. Durham

Published in: Current Pain and Headache Reports | Issue 8/2016

Login to get access

Abstract

The neuropeptide calcitonin gene-related peptide (CGRP) is implicated in the underlying pathology of migraine by promoting the development of a sensitized state of primary and secondary nociceptive neurons. The ability of CGRP to initiate and maintain peripheral and central sensitization is mediated by modulation of neuronal, glial, and immune cells in the trigeminal nociceptive signaling pathway. There is accumulating evidence to support a key role of CGRP in promoting cross excitation within the trigeminal ganglion that may help to explain the high co-morbidity of migraine with rhinosinusitis and temporomandibular joint disorder. In addition, there is emerging evidence that CGRP facilitates and sustains a hyperresponsive neuronal state in migraineurs mediated by reported risk factors such as stress and anxiety. In this review, the significant role of CGRP as a modulator of the trigeminal system will be discussed to provide a better understanding of the underlying pathology associated with the migraine phenotype.
Literature
1.
2.
Lipton R et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–57.CrossRefPubMed
3.
4.••
Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619–29. This is an excellent comprehensive review of our current understanding of migraine pathology.CrossRefPubMedPubMedCentral
5.
6.
Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394–402.CrossRefPubMed
7.
Goadsby P, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56.CrossRefPubMed
8.
Goadsby PJ, Edvinsson L, Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache. 1994;34(7):394–9.CrossRefPubMed
9.
Benemei S et al. Pain pharmacology in migraine: focus on CGRP and CGRP receptors. Neurol Sci. 2007;28 Suppl 2:S89–93.CrossRefPubMed
10.
Villalon CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009;124(3):309–23.CrossRefPubMed
11.
Goadsby P, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117:427–34.CrossRefPubMed
12.
Fanciullacci M et al. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain. 1995;60(2):119–23.CrossRefPubMed
13.
Durham P, Papapetropoulos S. Biomarkers associated with migraine and their potential role in migraine management. Headache. 2013;53(8):1262–77.CrossRefPubMed
14.
van Dongen RM et al. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia. 2016.
15.
Bigal, M.E., A.V. Krymchantowski, R. Hargreaves. The triptans. Expert Rev Neurother. 2009;9(5):649–59.
16.
Villalon, C.M., et al., Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003;1(1):71–84.
17.
Olesen J et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Eng J Med. 2004;350:1104–10.
18.
19.
Haut SR, Bigal ME, Lipton RB. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol. 2006;5(2):148–57.
20.
Ren K, Dubner R. Central nervous system plasticity and persistent pain. J Orofac Pain. 1999;13(3):155–63. discussion 164-71.PubMed
21.
Bellamy J et al. Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci. 2006;23(8):2057–66.CrossRefPubMedPubMedCentral
22.
Cady RK et al. Sinus headache: a neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatment. Mayo Clin Proc. 2005;80(7):908–16.
23.
Ballegaard V et al. Are headache and temporomandibular disorders related? A blinded study. Cephalalgia. 2008;28(8):832–41.CrossRefPubMed
24.
Bevilaqua Grossi D, Lipton RB, Bigal ME. Temporomandibular disorders and migraine chronification. Curr Pain Headache Rep. 2009;13(4):314–8.CrossRefPubMed
25.
Dahan H et al. Specific and number of comorbidities are associated with increased levels of temporomandibular pain intensity and duration. J Headache Pain. 2015;16:528.CrossRefPubMed
26.
Graff-Radford SB. Temporomandibular disorders and headache. Dent Clin N Am. 2007;51(1):129–44. vi-vii.CrossRefPubMed
27.
Amara S et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298:240–4.CrossRefPubMed
28.
Rosenfeld M et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983;304:129–35.CrossRefPubMed
29.
Fischer JA, Born W. Novel peptides from the calcitonin gene: expression, receptors and biological function. Peptides. 1985;6 Suppl 3:265–71.CrossRefPubMed
30.
Mulderry PK et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988;25(1):195–205.CrossRefPubMed
31.
Amara SG et al. Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science. 1985;229(4718):1094–7.CrossRefPubMed
32.
van Rossum D, Hanisch U, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21(5):649–78.CrossRefPubMed
33.
Wimalawansa S. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev. 1996;17(5):533–85.CrossRefPubMed
34.
Poyner D et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev. 2002;54(2):233–46.CrossRefPubMed
35.
Mallee J et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002;277(16):14294–8.CrossRefPubMed
36.•
Russell FA et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099–142. This review provides a thorough summary of the diverse physiological and pathophysiological roles of CGRP following its release from sensory neurons. CrossRefPubMedPubMedCentral
37.
Messlinger K, Fischer MJ, Lennerz JK. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. Keio J Med. 2011;60(3):82–9.CrossRefPubMed
38.
Zhang Z et al. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci. 2007;27(10):2693–703.CrossRefPubMed
39.
Li J, Vause C, Durham P. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res. 2008;1196:22–32.CrossRefPubMedPubMedCentral
40.
Thalakoti, S., et al., Neuron-Glia signaling in trigeminal ganglion: Implications for migraine pathology. Headache, 2007. 47(7): p. 1008–1023.
41.
42.
Peroutka SJ. Neurogenic inflammation and migraine: implications for the therapeutics. Mol Interv. 2005;5(5):304–11.CrossRefPubMed
43.
Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci U S A. 2004;101(12):4274–9.CrossRefPubMedPubMedCentral
44.
45.
Xie YF. Glial involvement in trigeminal central sensitization. Acta Pharmacol Sin. 2008;29(6):641–5.CrossRefPubMed
46.
Old EA, Clark AK, Malcangio M. The role of glia in the spinal cord in neuropathic and inflammatory pain. Handb Exp Pharmacol. 2015;227:145–70.CrossRefPubMed
47.
Durham PL, Russo AF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci. 1999;19(9):3423–9.PubMed
48.
Durham PL, Garrett FG. Emerging importance of neuron-satellite glia interactions within trigeminal ganglia in craniofacial pain. Open Pain J. 2010;3:3–13.
49.
Freeman S, Patil V, Durham P. Nitric oxide-proton stimulation of trigeminal ganglion neurons increases mitogen-activated protein kinase and phosphatase expression in neurons and satellite glial cells. Neuroscience. 2008;157:542–55.CrossRefPubMedPubMedCentral
50.
Vause CV, Durham PL. CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J Neurochem. 2009;110(3):811–21.CrossRefPubMedPubMedCentral
51.
52.
53.
Meng J et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009;29(15):4981–92.CrossRefPubMed
54.
Meng J et al. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120(Pt 16):2864–74.CrossRefPubMed
55.
Durham PL, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44(1):35–42. Discussion 42-3.CrossRefPubMed
56.
Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13 Suppl 4:1–9.CrossRefPubMed
57.
Bigal M et al. Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden. Headache. 2007;47(4):475–9.CrossRefPubMed
58.
Diener HC et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–14.CrossRefPubMed
59.
Durham PL, Masterson CG. Two mechanisms involved in trigeminal CGRP release: implications for migraine treatment. Headache. 2013;53(1):67–80.CrossRefPubMed
60.
Vause C et al. Effect of carbon dioxide on calcitonin gene-related peptide secretion from trigeminal neurons. Headache. 2007;47(10):1385–97.PubMedPubMedCentral
61.
Yan J et al. Dural afferents express acid-sensing ion channels: a role for decreased meningeal pH in migraine headache. Pain. 2011;152(1):106–13.CrossRefPubMed
62.
Bolay H, Moskowitz MA. Mechanisms of pain modulation in chronic syndromes. Neurology. 2002;59(5 Suppl 2):S2–7.CrossRefPubMed
63.
Hargreaves RJ, Shepheard SL. Pathophysiology of migraine—new insights. Can J Neurol Sci. 1999;26 Suppl 3:S12–9.CrossRefPubMed
64.
Mamet J et al. Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. J Neurosci. 2002;22(24):10662–70.PubMed
65.
Lingueglia E. Acid-sensing ion channels in sensory perception. J Biol Chem. 2007;282(24):17325–9.CrossRefPubMed
66.
Voilley N et al. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci. 2001;21(20):8026–33.PubMed
67.
Brandes JL et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007;297(13):1443–54.CrossRefPubMed
68.
Holland PR et al. Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol. 2012;72(4):559–63.CrossRefPubMed
69.
Cady RK, Schreiber CP. Sinus problems as a cause of headache refractoriness and migraine chronification. Curr Pain Headache Rep. 2009;13(4):319–25.CrossRefPubMed
70.
Oh EJ, Weinreich D. Chemical communication between vagal afferent somata in nodose ganglia of the rat and the guinea pig in vitro. J Neurophysiol. 2002;87:2801–7.PubMed
71.
Amir R, Devor M. Chemically mediated cross-excitation in rat dorsal root ganglia. J Neurosci. 1996;16(15):4733–41.PubMed
72.
Amir R, Devor M. Functional cross-excitation between afferent A- and C-neurons in dorsal root ganglia. Neuroscience. 2000;95(1):189–95.CrossRefPubMed
73.
Ulrich-Lai, Y.M., et al., Capsaicin-evoked release of immunoreactive calcitonin gene-related peptide from rat trigeminal ganglion: evidence for intraganglionic neurotransmission. Pain, 2001. 91(3): p. 219-26.
74.
75.
Neubert JK et al. Inflammation-induced changes in primary afferent-evoked release of substance P within trigeminal ganglia in vivo. Brain Res. 2000;871(2):181–91.CrossRefPubMed
76.
Arinci A et al. Molecular correlates of temporomandibular joint disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:666–70.CrossRefPubMed
77.
Takahashi T et al. Association between arthroscopic diagnosis of temporomandibular joint osteoarthritis and synovial fluid nitric oxide levels. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:129–36.CrossRefPubMed
78.
79.
Buse DC et al. Psychiatric comorbidities of episodic and chronic migraine. J Neurol. 2013;260(8):1960–9.CrossRefPubMed
80.
Barry CM et al. Sensory nerve fibers containing calcitonin gene-related peptide in gastrocnemius, latissimus dorsi and erector spinae muscles and thoracolumbar fascia in mice. Neuroscience. 2015;291:106–17.CrossRefPubMed
81.
Dudek A et al. Immunohistochemical properties of motoneurons supplying the trapezius muscle in the rat. Pol J Vet Sci. 2011;14(2):199–205.PubMed
82.
Tsukagoshi M, Goris RC, Funakoshi K. Differential distribution of vanilloid receptors in the primary sensory neurons projecting to the dorsal skin and muscles. Histochem Cell Biol. 2006;126(3):343–52.CrossRefPubMed
83.
Graven-Nielsen T, Arendt-Nielsen L. Peripheral and central sensitization in musculoskeletal pain disorders: an experimental approach. Curr Rheumatol Rep. 2002;4(4):313–21.CrossRefPubMed
84.
Neugebauer V, Rumenapp P, Schaible HG. Calcitonin gene-related peptide is involved in the spinal processing of mechanosensory input from the rat’s knee joint and in the generation and maintenance of hyperexcitability of dorsal horn-neurons during development of acute inflammation. Neuroscience. 1996;71(4):1095–109.CrossRefPubMed
85.
Sun R et al. Calcitonin gene-related peptide receptor activation produces PKA- and PKC-dependent mechanical hyperalgesia and central sensitization. J Neurophysiol. 2004;92:2859–66.CrossRefPubMed
86.
Yu LC, Hansson P, Lundeberg T. The calcitonin gene-related peptide antagonist CGRP8-37 increases the latency to withdrawal responses in rats. Brain Res. 1994;653(1-2):223–30.CrossRefPubMed
87.
Kawamura M et al. Antinociceptive effect of intrathecally administered antiserum against calcitonin gene-related peptide on thermal and mechanical noxious stimuli in experimental hyperalgesic rats. Brain Res. 1989;497(1):199–203.CrossRefPubMed
88.
Evidente VG, Adler CH. An update on the neurologic applications of botulinum toxins. Curr Neurol Neurosci Rep. 2010;10(5):338–44.CrossRefPubMed
89.
Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43 Suppl 1:S16–24.CrossRefPubMed
90.
Morch CD et al. Convergence of cutaneous, musculoskeletal, dural and visceral afferents onto nociceptive neurons in the first cervical dorsal horn. Eur J Neurosci. 2007;26(1):142–54.CrossRefPubMed
91.
Fernandez-de-las-Penas C et al. The role of myofascial trigger points in musculoskeletal pain syndromes of the head and neck. Curr Pain Headache Rep. 2007;11(5):365–72.CrossRefPubMed
92.
Lam DK, Sessle BJ, Hu JW. Glutamate and capsaicin effects on trigeminal nociception II: activation and central sensitization in brainstem neurons with deep craniofacial afferent input. Brain Res. 2009;1253:48–59.CrossRefPubMed
93.
Bach-Rojecky L, Lackovic Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav. 2009;94(2):234–8.CrossRefPubMed
94.
Gobel H et al. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain. 2006;125(1-2):82–8.CrossRefPubMed
95.•
Gungor NZ, Pare D. CGRP inhibits neurons of the bed nucleus of the stria terminalis: implications for the regulation of fear and anxiety. J Neurosci. 2014;34(1):60–5. This study provides evidence of the emerging role of CGRP in anxiety-related behaviors that is likely to have important implications for progression of migraine pathology. CrossRefPubMedPubMedCentral
96.
Choi DC et al. Bed nucleus of the stria terminalis subregions differentially regulate hypothalamic-pituitary-adrenal axis activity: implications for the integration of limbic inputs. J Neurosci. 2007;27(8):2025–34.CrossRefPubMed
97.
Rouwette T et al. The amygdala, a relay station for switching on and off pain. Eur J Pain. 2012;16(6):782–92.CrossRefPubMed
98.
99.
Metadata
Title
Diverse Physiological Roles of Calcitonin Gene-Related Peptide in Migraine Pathology: Modulation of Neuronal-Glial-Immune Cells to Promote Peripheral and Central Sensitization
Author
Paul L. Durham
Publication date
01-08-2016
Publisher
Springer US
Published in
Current Pain and Headache Reports / Issue 8/2016
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-016-0578-4